Investor Relations

Recent News
Jun 27, 2019

- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Exploring non-dilutive options to support future continued development of SRA737 and SRA141 -...

Jun 5, 2019

- Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK...

Jun 4, 2019

- MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 – - World renowned myelofibrosis expert Dr. Srdan Verstovsek named Chief...

View all news releases

Events and Webcasts
Tuesday, June 11, 2019
10:00am PDT

Location: Four Seasons Hotel, 791 West Georgia Street, Vancouver, British Columbia V6C 2T4

View all events and webcasts

Investor Enquiries

James Smith, Vice President Corporate Affairs

Sign up for investor alerts